Brief: Tempest Therapeutics reports Q2 results
Aug 15 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND
PROVIDES BUSINESS UPDATE
* TEMPEST THERAPEUTICS INC QTRLY LOSS PER SHARE$ $0.79
Source text for Eikon: ID:nGNXc6StyB
Further company coverage: TPST.O
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T